PPARGC1A and fatty liver disease: In the present study, we showed that enterocytes’ specific ablation of Pgc1α protects from hepatic steatosis and fibrosis driven by the WD via a reduction of intestinal cholesterol absorption, and subsequent decrease of cholesterol and de novo fatty acid accumulation in the liver.